• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·4974.T
Share

Takara Bio Inc. Stocks

¥ 1144Last Updated 11.06.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

¥ 854.08M

¥ 1144
Key Takeaways

Risk factor

Considerable default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Weak growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Takara Bio Inc., a subsidiary of Takara Holdings Inc., is a Japan-based biotechnology firm established in Kusatsu in 2002. The company operates globally, with a presence in Japan, China, other Asian countries, the United States, and Europe, focusing on three primary areas: general biotechnology, contract development and manufacturing (CDMO) services, and gene therapy. The company offers a diverse portfolio of scientific products, including a wide array of reagents and specialized instruments. These encompass tools for genetic research and testing, in vitro diagnostic solutions for viral detection (such as those for coronaviruses), analytical reagents, and advanced single-cell analysis systems. They also supply essential reagents for gene expression studies, fluorescent protein series, genome-editing research, iPS cell research, and products for culturing and differentiating stem cells. These offerings are marketed under prominent brands like TaKaRa, Clontech, and Cellartis. In addition to its product line, Takara Bio provides extensive contract services. For regenerative medicine, this includes the production of viral vectors and gene-modified cells, alongside rigorous quality and safety testing, and comprehensive cell banking services. Their gene analysis and testing services cover a broad spectrum, from DNA sequencing and gut microbiome analysis to in-depth profiling of cancer-associated genes and the creation of cell lines through genome editing. Furthermore, Takara Bio is actively engaged in developing foundational platform technologies to support the advancement of biologics, particularly within the field of gene therapy.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, neutral on EV/

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 4974.T is 1234 and suggests 7.85% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendat

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.07.2026 21:28

Apple Is Preparing for a Breakthrough in the Smart Home Market — Bloomberg

28.07.2026 21:08

An Nvidia-backed fiber-optic manufacturer is heading for its worst day in 24 years. Why?

28.07.2026 21:00

SpaceX lost $1.2 trillion in market capitalization before its stock rebounded from its low

28.07.2026 19:40

"A Pure Expression of Power": How Christopher Nolan's "Odyssey" Will Change IMAX

28.07.2026 19:12

The Nasdaq 100 has entered a correction phase. The "Wall Street fear" index jumped

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026